ECSP23083881A - Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 - Google Patents

Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8

Info

Publication number
ECSP23083881A
ECSP23083881A ECSENADI202383881A ECDI202383881A ECSP23083881A EC SP23083881 A ECSP23083881 A EC SP23083881A EC SENADI202383881 A ECSENADI202383881 A EC SENADI202383881A EC DI202383881 A ECDI202383881 A EC DI202383881A EC SP23083881 A ECSP23083881 A EC SP23083881A
Authority
EC
Ecuador
Prior art keywords
oxopiperazin
carboxamides
inhibitors
disorders
cycloheteroalkyl
Prior art date
Application number
ECSENADI202383881A
Other languages
English (en)
Inventor
Akshay A Shah
Jian Liu
Jason M Cox
Michael J Kelly Iii
Ashok Arasappan
Ian M Bell
Michael D Vanheyst
Hong Liu
Mark E Layton
Original Assignee
Merck Sharp Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp Dohme Llc filed Critical Merck Sharp Dohme Llc
Publication of ECSP23083881A publication Critical patent/ECSP23083881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los nuevos compuestos de fórmula estructural (I), y las sales farmacéuticamente aceptables de los mismos, son inhibidores de la actividad de los canales Nav1.8 y pueden ser útiles en el tratamiento, prevención, gestión, mejoría, control y supresión de enfermedades mediadas por la actividad de los canales Nav1.8. Los compuestos de Fórmula I pueden ser útiles en el tratamiento, prevención o gestión de trastornos de dolor, trastornos de tos, trastornos de picazón aguda y trastornos de picazón crónica.
ECSENADI202383881A 2021-05-07 2023-11-06 Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 ECSP23083881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163185637P 2021-05-07 2021-05-07
US202163286691P 2021-12-07 2021-12-07

Publications (1)

Publication Number Publication Date
ECSP23083881A true ECSP23083881A (es) 2023-12-29

Family

ID=81927873

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202383881A ECSP23083881A (es) 2021-05-07 2023-11-06 Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8

Country Status (16)

Country Link
US (1) US20220380338A1 (es)
EP (1) EP4334293A1 (es)
JP (1) JP7522943B2 (es)
KR (1) KR20240005878A (es)
AU (1) AU2022270115A1 (es)
BR (1) BR112023023239A2 (es)
CA (1) CA3217565A1 (es)
CL (1) CL2023003295A1 (es)
CO (1) CO2023015096A2 (es)
CR (1) CR20230519A (es)
DO (1) DOP2023000242A (es)
EC (1) ECSP23083881A (es)
IL (1) IL308215A (es)
MX (1) MX2023013146A (es)
TW (1) TWI827037B (es)
WO (1) WO2022235859A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
CN117645533B (zh) * 2023-10-20 2024-10-11 泰州精英化成医药科技有限公司 一种4-(三氟甲基)环己酮的合成方法
CN117567323A (zh) * 2023-10-30 2024-02-20 湖北泰盛化工有限公司 一种(s)-4-氯-2-((甲氧基羰基)氨基)丁酸乙酯的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115610B2 (en) 2003-12-18 2006-10-03 Cv Therapeutics, Inc. Substituted heterocyclic compounds
CA2702101A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
US8389734B2 (en) 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
CA2701946A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
US8629149B2 (en) 2009-09-04 2014-01-14 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8889863B2 (en) 2010-07-16 2014-11-18 Vanderbilt University Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds
SG11201505954RA (en) 2013-01-31 2015-08-28 Vertex Pharma Amides as modulators of sodium channels
UY35288A (es) 2013-01-31 2014-08-29 Vertex Pharma Piridonamidas como moduladores de canales de sodio
ES2620379T3 (es) 2013-01-31 2017-06-28 Vertex Pharmaceuticals Inc. Quinolina y quinoxalina amidas como moduladores de canales de sodio
CA2918365C (en) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
JP2017114764A (ja) 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
WO2015184383A1 (en) 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
WO2017209322A1 (ko) 2016-05-31 2017-12-07 한림대학교 산학협력단 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2018213426A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JOP20200001A1 (ar) 2017-07-11 2022-10-30 Vertex Pharma كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
CN111447930A (zh) 2017-11-23 2020-07-24 奥斯陆大学医院公司 心动过速的治疗
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
BR112021008524A8 (pt) * 2018-11-02 2023-02-07 Merck Sharp & Dohme 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8
EP3873468A4 (en) * 2018-11-02 2022-10-26 Merck Sharp & Dohme LLC 2-AMINO-N-PHENYL-NICOTINAMIDE USED AS NAV1.8 INHIBITORS
EP4065587A4 (en) 2019-11-26 2023-12-27 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
MX2022015580A (es) * 2020-06-17 2023-01-24 Merck Sharp & Dohme Llc 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8.
JP7323723B2 (ja) * 2020-06-17 2023-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド

Also Published As

Publication number Publication date
AU2022270115A1 (en) 2023-11-16
JP2024515895A (ja) 2024-04-10
US20220380338A1 (en) 2022-12-01
CO2023015096A2 (es) 2023-11-20
BR112023023239A2 (pt) 2024-01-23
CL2023003295A1 (es) 2024-07-12
TW202308999A (zh) 2023-03-01
KR20240005878A (ko) 2024-01-12
JP7522943B2 (ja) 2024-07-25
CR20230519A (es) 2024-01-19
EP4334293A1 (en) 2024-03-13
CA3217565A1 (en) 2022-11-10
DOP2023000242A (es) 2023-12-15
TWI827037B (zh) 2023-12-21
IL308215A (en) 2024-01-01
WO2022235859A1 (en) 2022-11-10
MX2023013146A (es) 2023-11-28

Similar Documents

Publication Publication Date Title
CO2023015096A2 (es) Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8
DOP2022000290A (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
DOP2021000082A (es) 2- amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8
MX2022015580A (es) 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8.
MX2022015579A (es) 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8.
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
MX2023013147A (es) Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
MX2019010381A (es) Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
UY38765A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
CL2021002878A1 (es) Tratamiento y prevención de enfermedades metabólicas
AR041942A1 (es) Derivados de 10-oxa -1-aza-dibenzo [a,d] ciclohepteno-7-carboxilico como antagonistas ccr1 para el tratamiento de la enfermedad desmielinizante inflamatoria
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
CO2024006030A2 (es) Compuestos de quinolina como inhibidores de kras
MX2024003459A (es) Metodos de tratamiento de trastornos metabolicos.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MD4879B1 (ro) Utilizare a derivatului bisamidic al acidului malonic pentru tratarea bolilor alergice şi altor boli umane şi animaliere
CL2022000329A1 (es) Agentes antipalúdicos.
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
EA202193211A1 (ru) Лечение синуклеопатий
AU2019284008A1 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
AR125786A1 (es) CICLOALQUIL 3-OXOPIPERAZIN CARBOXAMIDAS Y CICLOHETEROALQUIL 3-OXOPIPERAZIN CARBOXAMIDAS COMO INHIBIDORES DE Naᵛ1.8
EA201900418A1 (ru) Средство для терапии раневых или ожоговых поражений кожи